Concord Biotech logo

Concord Biotech

CONCORDBIO NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹15,120 Cr
Volatility
Moderate
P/E Ratio
55.89
EBITDA
₹420 Cr
Return on Equity
12.86%
Debt to Equity
0
Book Value
₹192.81
EPS
₹29.94
52W High
₹1,704
52W Low
₹987

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.2%

Weaknesses

3
  • Stock is trading at 7.80 times its book value
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has high debtors of 159 days.

Growth Rate

Revenue Growth
-11.03% lower than 3Y
Net Income Growth
-30.25% lower than 3Y
Cash Flow Change
9.14% higher than 3Y
ROE
-37.27% lower than 3Y
ROCE
-37.59% lower than 3Y
EBITDA Margin (Avg.)
-14.35% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk medium

Concord Biotech Ltd is a healthcare company with a market cap of ₹15,120 Cr trading at a PE of 55.7x and PB of 7.53x. The company is virtually debt-free with a 28.2% dividend payout, but recent performance shows a TTM sales decline of -6% and a TTM profit decline of -20%, marking a notable slowdown from its 10-year compounded sales CAGR of 14%.

Bull Case 7
  • Company is almost debt-free, significantly reducing financial risk and interest burden
  • Healthy dividend payout ratio of 28.2%, indicating consistent cash return to shareholders
  • Long-term compounded sales CAGR of 14% over 10 years demonstrates a sustained revenue growth track record
  • 10-year compounded profit CAGR of 11% shows the company has historically been able to grow earnings over extended periods
  • 3-year and 5-year ROE of 18% reflects efficient use of shareholder equity over medium-term horizons
  • 5-year compounded sales CAGR of 11% indicates reasonable top-line momentum prior to the recent slowdown
  • Company has actively reduced debt, strengthening its balance sheet for future expansion or downturns
Bear Case 8
  • PE ratio of 55.7x is significantly elevated, pricing in substantial future growth that recent trends do not support
  • TTM sales growth has turned negative at -6%, a sharp reversal from the 10-year CAGR of 14%
  • TTM profit has declined -20%, indicating severe margin pressure or operational challenges
  • Stock is trading at 7.53x book value, leaving limited margin of safety for investors
  • 3-year compounded profit CAGR is just 1%, showing earnings stagnation over the medium term
  • High debtor days of 159 days suggest working capital inefficiency and potential collection risk
  • Last year ROE dropped to 13% from the 3-year and 5-year average of 18%, signaling declining capital efficiency
  • 1-year stock return of -11% reflects market concern about the company's near-term trajectory

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Neutral 1
  • Investor meet on Aug 26 Aug 21

    Concord Biotech will host a group meeting with analysts and institutional investors on August 26, 2026, in Ahmedabad, organized by Phillip Capital PCG. The session will cover publicly available information only.

TL;DR: Limited recent news flow for Concord Biotech with only a routine investor meeting scheduled for Aug 26. No material headwinds or positive catalysts emerged in this period. The lack of negative news is mildly reassuring, but investors should watch for any updates or guidance that may come out of the upcoming analyst meet.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
195
262
241
319
216
310
244
430
204
247
278
326
261
Expenses
123
143
135
185
135
174
146
239
143
157
176
204
173
Operating Profit
72
119
106
134
81
137
98
190
61
91
102
122
87
OPM %
37%
45%
44%
42%
38%
44%
40%
44%
30%
37%
37%
38%
33%
Other Income
7
8
8
11
10
10
15
9
14
13
7
16
13
Interest
1
1
0
0
0
0
0
0
0
0
0
0
0
Depreciation
13
13
14
14
13
13
13
15
18
18
19
19
18
PBT
65
113
100
131
78
133
99
185
57
86
90
118
82
Tax %
25%
25%
26%
26%
25%
26%
25%
23%
26%
26%
25%
24%
26%
Net Profit
48
84
75
97
58
99
74
142
43
63
68
90
61
EPS in Rs
4.63
8.08
7.13
9.29
5.57
9.43
7.08
13.57
4.07
6.01
6.48
8.6
5.85
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
239
276
340
436
512
617
713
853
1,017
1,200
1,055
1,112
Expenses
133
145
212
256
308
289
439
509
585
693
678
709
Operating Profit
105
131
127
180
205
328
274
344
432
507
377
402
OPM %
44%
48%
37%
41%
40%
53%
38%
40%
42%
42%
36%
36%
Other Income
11
8
36
17
31
14
23
35
34
44
49
49
Interest
1
0
1
1
1
1
6
5
3
1
1
0
Depreciation
10
10
18
19
21
28
50
54
54
54
74
75
PBT
106
129
144
178
213
313
241
320
409
496
351
376
Tax %
34%
33%
30%
33%
21%
25%
26%
26%
26%
25%
25%
—
Net Profit
70
87
100
118
169
235
179
238
305
373
263
282
EPS in Rs
76.32
94.78
106
124
178
247
188
22.76
29.13
35.65
25.17
26.94
Div. Payout %
22%
25%
0%
21%
22%
0%
3%
30%
30%
25%
30%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
10
10
10
10
10
10
10
10
10
Reserves
268
329
585
673
761
990
1,098
1,282
1,515
1,802
2,009
Borrowings
35
36
22
9
52
89
62
32
10
3
1
Other Liabilities
55
74
69
71
118
94
144
191
164
219
216
Total Liabilities
367
448
685
763
941
1,183
1,313
1,515
1,699
2,034
2,237
Fixed Assets
104
110
189
230
240
546
573
593
575
795
786
CWIP
19
70
3
19
141
18
74
173
211
51
79
Investments
42
43
151
229
199
142
74
138
244
335
488
Other Assets
202
225
343
285
361
477
592
611
668
854
883
Total Assets
367
448
685
763
941
1,183
1,313
1,515
1,699
2,034
2,237
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
79
—
155
167
207
246
265
245
264
Investing
—
—
-42
—
-114
-195
-112
-158
-155
-160
-142
Financing
—
—
-37
—
-43
31
-100
-85
-99
-99
-115
Net Cash Flow
—
—
0
—
-1
3
-4
3
12
-14
7
Free Cash Flow
—
—
79
—
-1
-37
52
101
180
134
169
CFO/OP
—
—
101
—
100
74
98
92
85
70
96
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
165
182
236
133
131
105
119
117
125
159
159
Inventory Days
276
321
381
310
312
503
434
430
331
286
483
Days Payable
108
129
210
112
201
152
185
190
150
135
150
Cash Conversion Cycle
334
374
407
331
242
456
368
357
306
310
492
Working Capital Days
195
209
275
177
159
177
163
153
166
193
231
ROCE %
—
37%
—
25%
25%
32%
21%
26%
28%
28%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Concord Biotech insights

68 extracted metrics + investor summaries across FY15–FY27.

Log in — free

Shareholding Pattern

FIIs7.52%Promot.44.08%Public8.23%DIIs9.36%Others30.81%As ofJun 2026

Documents

Frequently Asked Questions about Concord Biotech

What does Concord Biotech Ltd do?
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
Where is Concord Biotech Ltd (CONCORDBIO) listed?
Concord Biotech Ltd trades as CONCORDBIO on the NSE and under code 543960 on the BSE.
Which sector does Concord Biotech Ltd belong to?
Concord Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Concord Biotech Ltd?
Concord Biotech Ltd has a market capitalisation of ₹15,120 Cr, which places it in the Mid Cap band.
What is the PE ratio of Concord Biotech Ltd?
Concord Biotech Ltd trades at a PE ratio of 55.89, on earnings per share of ₹29.94, against a book value of ₹192.81 per share.
What is the 52-week high and low of Concord Biotech Ltd?
Over the last 52 weeks Concord Biotech Ltd has traded between ₹987 and ₹1,704.
Does Concord Biotech Ltd pay dividends?
Concord Biotech Ltd has a dividend yield of 0.52%.
What is the Return on Equity (ROE) of Concord Biotech Ltd?
Concord Biotech Ltd reported a return on equity of 12.86%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Website concordbiotech.com
CEO Mr. Sudhir Jairam Vaid
Employees 1,571
Listed 2023-08-18
Face Value ₹ 1
Issued Size 10,46,16,204

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CONCORDBIO.md for Concord Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List